These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37253161)

  • 1. Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition.
    Mallaroni P; Mason NL; Reckweg JT; Paci R; Ritscher S; Toennes SW; Theunissen EL; Kuypers KPC; Ramaekers JG
    Clin Pharmacol Ther; 2023 Aug; 114(2):423-433. PubMed ID: 37253161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
    Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study.
    Papaseit E; Farré M; Pérez-Mañá C; Torrens M; Ventura M; Pujadas M; de la Torre R; González D
    Front Pharmacol; 2018; 9():206. PubMed ID: 29593537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.
    Viktorin V; Griškova-Bulanova I; Voicikas A; Dojčánová D; Zach P; Bravermanová A; Andrashko V; Tylš F; Korčák J; Viktorinová M; Koudelka V; Hájková K; Kuchař M; Horáček J; Brunovský M; Páleníček T
    J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.
    Mason NL; Kuypers KPC; Müller F; Reckweg J; Tse DHY; Toennes SW; Hutten NRPW; Jansen JFA; Stiers P; Feilding A; Ramaekers JG
    Neuropsychopharmacology; 2020 Nov; 45(12):2003-2011. PubMed ID: 32446245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
    Carbonaro TM; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Effects of 2C-E in Humans: An Observational Study.
    Papaseit E; Olesti E; Pérez-Mañá C; Torrens M; Grifell M; Ventura M; Pozo OJ; de Sousa Fernandes Perna EB; Ramaekers JG; de la Torre R; Farré M
    Front Pharmacol; 2020; 11():233. PubMed ID: 32256350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
    Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
    Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
    Smigielski L; Scheidegger M; Kometer M; Vollenweider FX
    Neuroimage; 2019 Aug; 196():207-215. PubMed ID: 30965131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
    Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL
    Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.